GlassScriptPhysician profile
Richard M Young
NPI 1326097205
$3,740.84
in general payments reported to CMS, 2019-2025
19 companies · $76.13 in 2025
The $76.13 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $305 · 2020: $358 · 2022: $448 · 2023: $1,925 · 2024: $629 · 2025: $76.13.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,803 · Travel and Lodging: $827.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,802.89 |
| Travel and Lodging | $826.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Procept Biorobotics Corporation | $877.71 | 2023-2024 | Aquabeam Robotic System, Aquabeam System |
| Astrazeneca Pharmaceuticals LP | $544.14 | 2022-2024 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $530.67 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $444.79 | 2019-2024 | Evenity, Repatha, Otezla |
| Novo Nordisk INC | $318.37 | 2020-2024 | Rybelsus, Ozempic |
| Lilly USA, LLC | $228.14 | 2023-2024 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $214.71 | 2019-2025 | |
| Mylan Specialty L.P. | $143.30 | 2023 | Yupelri, Yupelri |
| E.R. Squibb & Sons, L.L.C. | $122.04 | 2020 | |
| Boston Scientific Corporation | $121.51 | 2020 | |
| Exact Sciences Corporation | $44.61 | 2023-2024 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $33.78 | 2024 | Voquezna |
| Idorsia Pharmaceuticals US INC | $26.18 | 2023 | Quviviq |
| Abbott Laboratories | $22.51 | 2023 | Freestyle Libre 2 |
| Eisai INC. | $21.21 | 2024 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| La Jolla Pharmaceutical Company | $16.81 | 2020 | |
| Janssen Pharmaceuticals, INC | $16.78 | 2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.58 | 2023 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$94,047.50 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.